Roberto Andini
Impact in
- Molecular Medicine top 0.2%
- Antibiotic Resistance in Bacteria
-
- Antibiotic Use and Resistance
Papers in
-
- Antibiotic Resistance in Bacteria 19
-
- COVID-19 Clinical Research Studies 7
- Antimicrobial Resistance in Staphylococcus 5
- Co-authors
- Emanuele Durante‐Mangoni (32 shared papers)Antonio Corcione (7 shared papers)Rosa Zampino (18 shared papers)Riccardo Utili (8 shared papers)Patrizia Murino (4 shared papers)Raffaele Zarrilli (3 shared papers)Nicola Galdieri (3 shared papers)Nicola Petrosillo (2 shared papers)
In The Last Decade
Roberto Andini
52 papers receiving 2.0k citations
Roberto Andini's Hit Papers
Peers
Comparison fields: 5 of 102
- Molecular Medicine 1.1k
- Applied Microbiology and Biotechnology 297
- Endocrinology 163
- Pharmacology 483
- Critical Care and Intensive Care Medicine 112
Countries citing papers authored by Roberto Andini
This map shows the geographic impact of Roberto Andini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Andini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Andini more than expected).
Fields of papers citing papers by Roberto Andini
This network shows the impact of papers produced by Roberto Andini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Andini. The network helps show where Roberto Andini may publish in the future.
Co-authors
The 25 scholars most cited alongside Roberto Andini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial Hit paper breakdown → | 2018 | 509 |
| 2 | 2013 | 359 | |
| 3 | 2020 | 113 | |
| 4 | 2018 | 103 | |
| 5 | 2021 | 78 | |
| 6 | 2021 | 67 | |
| 7 | 2020 | 64 | |
| 8 | 2021 | 60 | |
| 9 | 2022 | 58 | |
| 10 | 2015 | 51 | |
| 11 | 2021 | 51 | |
| 12 | 2016 | 39 | |
| 13 | 2018 | 38 | |
| 14 | 2023 | 36 | |
| 15 | 2020 | 27 | |
| 16 | 2016 | 25 | |
| 17 | 2022 | 25 | |
| 18 | 2022 | 23 | |
| 19 | 2023 | 22 | |
| 20 | 2020 | 22 |
About Roberto Andini
Roberto Andini is a scholar working on Molecular Medicine, Infectious Diseases, Epidemiology, Pharmacology and Applied Microbiology and Biotechnology, having authored 54 papers that have together received 2.0k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (19 papers), Infective Endocarditis Diagnosis and Management (9 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers), COVID-19 Clinical Research Studies (7 papers), Antimicrobial Resistance in Staphylococcus (5 papers), Transplantation: Methods and Outcomes (4 papers), Pneumonia and Respiratory Infections (3 papers) and Long-Term Effects of COVID-19 (3 papers). The work is most often cited by research in Molecular Medicine (1.1k citations), Applied Microbiology and Biotechnology (297 citations), Endocrinology (163 citations), Pharmacology (483 citations) and Critical Care and Intensive Care Medicine (112 citations). Roberto Andini has collaborated with scholars based in Italy, Israel and Greece. Frequent co-authors include Emanuele Durante‐Mangoni, Antonio Corcione, Rosa Zampino, Riccardo Utili, Patrizia Murino, Raffaele Zarrilli, Nicola Galdieri, Nicola Petrosillo, Lorenzo Bertolino and Claudio Viscoli. Their work appears in journals such as Infection, Clinical Infectious Diseases, International Journal of Antimicrobial Agents, Journal of Chemotherapy and Clinical Microbiology and Infection.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.